Completed Cancer NIHR-supported project Digestion, Kidneys & Other Organs
An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA10.1 injection in men with metastatic castrate resistant prostate cancer
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Amarnath Challipalli (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A multi-site, prospective, open-label Phase I/II trial of Actinium (225Ac) rhPSMA 10.1 to evaluate safety and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously responded to Lutetium-PSMA.
CAAA617A12101: A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
CAAA617A12101: A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer.
ACT-RESoLUTE - A multi-site, prospective, open-label Phase I/II trial of Actinium (225Ac) rhPSMA-10.1 to evaluate safety and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (mCRPC) including those who have previously responded to Lutetium-PSMA
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know